Scholarlink

<p>Concerns of increased metabolic dysfunction have been heightened for HIV patients on long-term antiretroviral therapy (ART). Among first-line ART agents, Tenofovir alafenamide (TAF) may entail a marked increase in weight compared to Tenofovir disoproxil fumarate (TDF). We retrospectively evaluated changes in weight and glucose regulation among 153 treament-naïve patients. Weight-gain was more pronounced after one year of treatment with TAF versus TDF (3.5&#xa0;kg versus − 1&#xa0;kg, <i>P</i>-value &lt; 0.001). However, weight-gain was attenuated with longer follow-up, and no increase in glucose dysregulation was noted for TAF treatment. Attribution of increased metabolic risk to treatment with TAF remains questionable.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Brief communication: comparison of changes in metabolic parameters following antiretrovial therapy with treatment regimens containing tenofovir alafenamide and tenofovir disoproxil fumarate

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年3月15日

查看全文
  • Hamed Mirmoezzi,
  • Hamid Emadi Koochak,
  • Seyed Ali Dehghan Manshadi,
  • Malihe Hasannezhad,
  • SeyedAhmad SeyedAlinaghi,
  • Kiavash Semnani,
  • Ladan Abbasian,
  • Sara Ghaderkhani

摘要

Concerns of increased metabolic dysfunction have been heightened for HIV patients on long-term antiretroviral therapy (ART). Among first-line ART agents, Tenofovir alafenamide (TAF) may entail a marked increase in weight compared to Tenofovir disoproxil fumarate (TDF). We retrospectively evaluated changes in weight and glucose regulation among 153 treament-naïve patients. Weight-gain was more pronounced after one year of treatment with TAF versus TDF (3.5 kg versus − 1 kg, P-value < 0.001). However, weight-gain was attenuated with longer follow-up, and no increase in glucose dysregulation was noted for TAF treatment. Attribution of increased metabolic risk to treatment with TAF remains questionable.